Osilodrostat
Cushing Disease Due to Increased ACTH Secretion
University of BasrahSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Cushing Disease Due to Increased ACTH Secretion cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cabergoline University of Basrah | Phase 4 | BB |
Pasireotide RECORDATI GROUP | Phase 4 | B |
Same molecule, other indications
Osilodrostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →